Pharmaceutical

UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1

The UK MHRA approved two formulations of ViiV Healthcare’s cabotegravir, offering a new prevention option for HIV-1 infection.

May 7, 2024 - 00:00
UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1
The UK MHRA approved two formulations of ViiV Healthcare’s cabotegravir, offering a new prevention option for HIV-1 infection.
Read the original article

Tags:

Previous Article

Lantern Pharma and Oregon partner to develop cancer treatment

Next Article

Sentynl acquires Eiger’s Zokinvy for progeria treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pharma readies for climate disasters amidst supply chain concerns

Pharma readies for climate disasters amidst supply chai...

Dec 14, 2023

Novartis and Versant launch Borealis Biosciences with $150m

Novartis and Versant launch Borealis Biosciences with $...

Aug 23, 2024

STAT+: More drugmakers are filing continuation patents that sideline generic competition

STAT+: More drugmakers are filing continuation patents ...

Aug 9, 2023